Amyloid Beta and the Immune System: Repurposing Neurodegenerative Pathways for Cancer Immunotherapy

Amyloid beta (Aβ), which was previously recognized predominantly for its neurotoxic properties in Alzheimer's disease, is now being acknowledged for its unforeseen potential to inhibit oncogenic proliferation. Recent research indicates that Aβ can enhance tumor antigen presentation and invigorate the activity of innate immune cells. This observation aligns with the established inverse relationship between neurodegeneration and cancer, which modifies the tumor microenvironment in an anti-cancer manner. Antitumor immunity is amplified through Aβ-induced microglial activation and cytokine production, which emulates the modulation of immunological checkpoints. These findings contribute to the development of innovative immunotherapeutic strategies that modulate neuroinflammatory signals and peptides derived from Aβ. Researchers are integrating the fields of oncology and neurology to precisely target cancer treatment by harnessing Aβ's immune-enhancing attributes while ensuring neuroprotection. This presents novel avenues for repurposing neurodegenerative pathways in the pursuit of precision cancer therapy.

Amyloid beta, Neuroinflammation, Antitumor immunity, Tumor microenvironment, Immunotherapy, Neuroprotection, Microglial Activation, cytokine production, Precision oncology, Peptide modulation.

1. Ontiersin.org. Amyloid Beta and Immune Modulation in Cancer Immunotherapy. Front Immunol [Internet]. 2025 [cited 2025 Oct 17]; Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1528363/full [Google Scholar] [Crossref]

2. Zhang H, Mehta P, Wang Y, et al. Recent advances in immunotherapy targeting amyloid-beta. PMC [Internet]. 2025 [cited 2025 Oct 17]; Available from: https://www.ncbi.nlm.nih.gov/pmc [Google Scholar] [Crossref]

3. Wang L, Patel R, Huang J, et al. Amyloid-β precursor protein promotes tumor growth by modulating mitochondrial metabolism. bioRxiv [Preprint]. 2025. [Google Scholar] [Crossref]

4. Liu R, Banerjee S, O’Connor D, et al. Mitochondrial dysfunction in Alzheimer’s disease. Science Direct [Internet]. 2025 [cited 2025 Oct 17]; Available from: https://www.sciencedirect.com [Google Scholar] [Crossref]

5. Bautista R, Lee S, Morgan J, et al. Inflammasome-driven metabolic reprogramming in neurodegeneration and cancer. J Transl Med. 2025;23(1):445–57. [Google Scholar] [Crossref]

6. Medscape. Cancer drugs could treat Alzheimer’s: Drug repurposing shows promise. Medscape [Internet]. 2025 [cited 2025 Oct 17]; Available from: https://www.medscape.com [Google Scholar] [Crossref]

7. Rossi M, Tanaka K, Li F, et al. Memory/active T-cell activation is associated with amyloid β-dependent mitochondrial maintenance. PubMed [Internet]. 2024 [cited 2025 Oct 17]; Available from: https://pubmed.ncbi.nlm.nih.gov [Google Scholar] [Crossref]

8. Wen T, Zhao M, Park J, et al. Mitochondrial transplantation reprograms immune metabolism in age-associated cancer models. OncoImmunology. 2025;14(2): e2336417. [Google Scholar] [Crossref]

9. Ito Y, Fernandez C, Muller R, et al. Mitochondrial protein translocation machinery: From TOM complex to cellular dynamics. PMC. 2022;18(4):561–70. [Google Scholar] [Crossref]

10. Gupta N, Zhao L, Kim S, et al. Interactions between amyloid, amyloid precursor protein, and mitochondria. Biomed Central. 2023;23(1):115–27. [Google Scholar] [Crossref]

11. Chen D, Park J, Lin Q, et al. Oncometabolite fumarate facilitates PD-L1 expression and immunosuppression in cancer. Nature. 2025;626(7892):214–22. [Google Scholar] [Crossref]

12. Cancer Research Institute. Supercharging T cells to fight cancer: A revolutionary discovery. Cancer Research Institute [Internet]. 2024 [cited 2025 Oct 17]; Available from: https://www.cancerresearch.org [Google Scholar] [Crossref]

13. Yu W, Martin C, Zhao Y, et al. Mitochondrial transplantation sensitizes chemotherapy to overcome immunosuppression. PubMed [Internet]. 2025 [cited 2025 Oct 17]; Available from: https://pubmed.ncbi.nlm.nih.gov [Google Scholar] [Crossref]

14. Keller J, Thompson E, Ramirez M, et al. Dimethyl fumarate treatment restrains the antioxidative response in primary progressive multiple sclerosis. Brain. 2021;144(8):2538–54. [Google Scholar] [Crossref]

15. Li J, Torres M, Ahmed S, et al. Alzheimer’s disease drug development pipeline: 2025. PMC [Internet]. 2025 [cited 2025 Oct 17]; Available from: https://www.ncbi.nlm.nih.gov/pmc [Google Scholar] [Crossref]

16. Smith A, Kaur G, Zhao T, et al. Amyloid precursor protein promotes lung cancer growth and confers resistance to immunotherapy. Duke Space [Internet]. 2025 [cited 2025 Oct 17]. [Google Scholar] [Crossref]

• QbD Approach to Hplc Method Development and Validation of the Simultaneous Estimation of Sulbactum and Durlobactum in Pharmaceutical Dosage Form
• A Review on an Evaluation of a Liposomal Hydrogel for Combined Minoxidil and Tretinoin Delivery in Androgenetic Alopecia
• Qualitative Screening and Analysis of Lunasia amara Blanco (Tawal-ulad) Ethanolic Leaves Extract as Potential Anti-Angiogenic Inhibitors Using the Chorioallantoic Membrane Assay on Mallard Duck Embryo
• A Comprehensive Review on Calotropis Procera on Its Analgesic Activity
• Formulation, Characterization and In-Vitro Evaluation of Curcumin Loaded Liposome for Colon Drug delivery